86 related articles for article (PubMed ID: 25131)
1. Comparison of enzymatic activities of two deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.
Meyers MB; Kreis W
Cancer Res; 1978 Apr; 38(4):1105-12. PubMed ID: 25131
[No Abstract] [Full Text] [Related]
2. Structural comparison of deoxycytidine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-beta-D-arabinofuranosylcytosine.
Meyers MB; Kreis W
Cancer Res; 1978 Apr; 38(4):1099-104. PubMed ID: 639039
[No Abstract] [Full Text] [Related]
3. Substrate-specific deoxycytidine kinase deficiency in 1-beta-D-arabinofuranosylcytosine-resistant leukemic cells.
Richel DJ; Colly LP; Arkesteijn GJ; Arentsen-Honders MW; Kerster MG; ter Riet PM; Willemze R
Cancer Res; 1990 Oct; 50(20):6515-9. PubMed ID: 2208110
[TBL] [Abstract][Full Text] [Related]
4. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
Bhalla K; Nayak R; Grant S
Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
[TBL] [Abstract][Full Text] [Related]
5. Characterization of protein and DNA in P815 cells sensitive and resistant to 1- -D-arabinofuranosylcytosine.
Kreis W; Drahovsky D; Borberg H
Cancer Res; 1972 Apr; 32(4):696-701. PubMed ID: 4622581
[No Abstract] [Full Text] [Related]
6. Elevated level of enzymatic DNA methylation in cells treated with 1-beta-D-arabinofuranosylcytosine.
Boehm TL; Drahovsky D
Cancer Res; 1982 Apr; 42(4):1537-40. PubMed ID: 7060025
[TBL] [Abstract][Full Text] [Related]
7. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylation of selected substrates by semipurified cytoplasmic kinases of three P815 murine leukemias exhibiting collateral sensitivity (P815/TG), sensitivity (P815) or resistance (P815/ARA-C) to 1-beta-D-arabinofuranosylcytosine.
Kreis W; Graham J; Damin LA
Biochem Pharmacol; 1982 Dec; 31(23):3831-7. PubMed ID: 6297500
[No Abstract] [Full Text] [Related]
9. Kinase and deaminase activity in a variety of subcutaneous mouse tumors.
Furner RL; Mellett LB
Cancer Res; 1975 Jul; 35(7):1799-803. PubMed ID: 165884
[TBL] [Abstract][Full Text] [Related]
10. Influence of tetrahydrouridine on the phosphorylation of 1-beta-D-arabinofuranosyl-cytosine (ara-C) by enzymes from solid tumors in vitro.
Furner RL; Mellett LB; Herren TC
J Pharmacol Exp Ther; 1975 Jul; 194(1):103-10. PubMed ID: 1057009
[TBL] [Abstract][Full Text] [Related]
11. Deoxycytidine kinase. I. Distribution in normal and neoplastic tissues and interrelationships of deoxycytidine and 1-beta-D-arabinofuranosylcytosine phosphorylation.
Durham JP; Ives DH
Mol Pharmacol; 1969 Jul; 5(4):358-75. PubMed ID: 4308509
[No Abstract] [Full Text] [Related]
12. Deoxycytidine kinase and cytosine nucleoside deaminase activities in synchronized cultures of normal rat kidney cells.
Wan CW; Mak TW
Cancer Res; 1978 Sep; 38(9):2768-72. PubMed ID: 679182
[TBL] [Abstract][Full Text] [Related]
13. Physiologic disposition of cytosine arabinoside and its derivatives in man.
Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
[TBL] [Abstract][Full Text] [Related]
14. Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells.
Lee T; Karon M; Monparler RL
Cancer Res; 1975 Sep; 35(9):2506-10. PubMed ID: 50132
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase.
Brockman RW; Cheng YC; Schabel FM; Montgomery JA
Cancer Res; 1980 Oct; 40(10):3610-5. PubMed ID: 6254636
[TBL] [Abstract][Full Text] [Related]
16. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
Kong XB; Tong WP; Chou TC
Mol Pharmacol; 1991 Feb; 39(2):250-7. PubMed ID: 1705001
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
[TBL] [Abstract][Full Text] [Related]
18. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
19. Flow microfluorimetric analysis of sensitive and resistant leukemia L1210 following 1-beta-D-arabinofuranosylcytosine in vivo.
Alabaster O; Bunnag B
Cancer Res; 1976 Aug; 36(8):2744-9. PubMed ID: 1277184
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
